Mifeprex (mifepristone) / Danco Laboratories 
Welcome,         Profile    Billing    Logout  
 94 Diseases   58 Trials   58 Trials   2914 News 


«12345678910111213...3839»
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Mifeprex (mifepristone) / Danco Laboratories
    Journal, BRCA Biomarker, PD(L)-1 Biomarker:  Antiprogestins for breast cancer treatment: we are almost ready. (Pubmed Central) -  May 30, 2024   
    Finally, we explain how transcriptomic or proteomic studies, that were carried out in different luminal breast cancer models and in breast cancer samples that responded or were predicted to respond to the antiprogestin therapy, show a decrease in proliferative pathways. Deregulated pathways intrinsic of each model are discussed, as well as how these analyses may contribute to a better understanding of the mechanisms involved.
  • ||||||||||  Mifeprex (mifepristone) / Danco Laboratories
    Journal:  Hyaline fibromatosis syndrome: a rare, yet recognizable syndrome. (Pubmed Central) -  May 30, 2024   
    HFS can be recognized easily with distinctive clinical features. Nevertheless, it has poor prognosis with increased mortality due to severe clinical decompensation.
  • ||||||||||  Mifeprex (mifepristone) / Danco Laboratories
    Preclinical, Journal, IO biomarker:  Effect of Shoutai Pills on expression of key glycolytic proteins and apoptosis related factors at maternal fetal interface in mouse model of threatened abortion with syndrome of kidney deficiency (Pubmed Central) -  May 30, 2024   
    At 16:00 every day, mice in the normal group were administrated with an equal volume of distilled water, while those in the model, Shoutai Pills, and dydrogesterone groups were administrated with hydrocortisone solution by gavage for 4 consecutive days...On day 6, mice were administrated with mifepristone by gavage to establish the model of kidney deficiency-induced abortion...Compared with the model group, dydrogesterone and Shoutai Pills reduced the apoptosis rate(P<0.05). In conclusion, Shoutai Pills can reduce the embryo loss rate and protect embryos by promoting aerobic glycolysis at the maternal-fetal interface and inhibiting the apoptosis of trophoblasts in mice.
  • ||||||||||  Mifeprex (mifepristone) / Danco Laboratories
    Review, Journal:  How Effective Is Misoprostol Alone for Medication Abortion? (Pubmed Central) -  May 28, 2024   
    AbstractWith recent severe restrictions to abortion accessibility in the United States and a pending Supreme Court case challenging the Food and Drug Administration's approval of mifepristone, evidence-based strategies to protect and expand access to abortion care are needed...To characterize the data supporting this specific regimen, this article reviews the relevant literature to address the question of how effective misoprostol-only is for medication abortion. The authors conclude that the updated misoprostol regimen is highly effective and a potential strategy for expanding access to abortion.
  • ||||||||||  Mifeprex (mifepristone) / Danco Laboratories
    Journal:  United Kingdom Data Deficiencies Influencing U.S. FDA Decisions. (Pubmed Central) -  May 21, 2024   
    The U.S. FDA has permanently removed the in-person prescribing requirements that previously safeguarded the use of mifepristone/misoprostol medical abortions, allowing prescribing through telemedicine or on-line ordering and distribution through the mail and pharmacies, without standard pre-abortion testing...The FDA justified this action by referencing flawed studies with significantly undercounted complications. The details of these study deficiencies are examined in this paper.
  • ||||||||||  Mifeprex (mifepristone) / Danco Laboratories
    Journal:  Mail-Order Pharmacy Dispensing of Mifepristone for Medication Abortion After In-Person Screening. (Pubmed Central) -  May 13, 2024   
    The findings of this cohort study indicate that mail-order pharmacy dispensing of mifepristone for medication abortion was effective, acceptable to patients, and feasible, with a low prevalence of serious adverse events. This care model should be expanded to improve access to medication abortion services.
  • ||||||||||  Mifeprex (mifepristone) / Danco Laboratories
    Journal, Adverse events:  The RU486-dependent activation of the GeneSwitch system in adult muscles leads to severe adverse effects in Drosophila. (Pubmed Central) -  May 7, 2024   
    Thus, researchers should be cautious when interpreting the results given the adverse effects we found when inducing RU486-dependent MHC-GS-GAL4 in adult muscles. To account for the impact of these effects we recommend adjusting the dose of RU486, setting up additional control groups, such as a mock UAS-RNAi transgene, to validate the findings when using this inducible genetic system, as comparing the phenotypes between RU486-treated and untreated animals could be insufficient.
  • ||||||||||  Preclinical, Journal:  Testing of putative antiseizure medications in a preclinical Dravet syndrome zebrafish model. (Pubmed Central) -  May 6, 2024   
    Thus far, we have screened more than 3000 drug candidates in scn1lab zebrafish mutants, identifying valproate, stiripentol, and fenfluramine e.g. Food and Drug Administration-approved drugs, with clinical application in the Dravet syndrome population...Here, we curated a list of nine anti-seizure drug candidates recently identified by other groups using preclinical Dravet syndrome models: 1-Ethyl-2-benzimidazolinone, AA43279, chlorzoxazone, donepezil, lisuride, mifepristone, pargyline, soticlestat and vorinostat...Surprisingly, soticlestat induced frank electrographic seizure-like discharges in wild-type control zebrafish. Taken together, our results failed to replicate clear anti-seizure efficacy for these drug candidates highlighting a necessity for strict scientific standards in preclinical identification of anti-seizure medications.
  • ||||||||||  Mifeprex (mifepristone) / Danco Laboratories
    Journal:  MIFEPRISTON IN OBSTETRICS - WHY NOT? (Pubmed Central) -  Apr 17, 2024   
    Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2023 --> Dec 2024 In the study group the rate of vaginal delivery was higher and the frequency of cesarean section was lower compared to the control group (75 vs. 72, and 13 vs. 15, respectively); The total duration of labour was shorter in the study group (p0,05); The pain level was significantly low in the study group compared to the control group (5
  • ||||||||||  Mifeprex (mifepristone) / Danco Laboratories
    Preclinical, Journal:  Effects of mifepristone on adipocyte differentiation in mouse 3T3-L1 cells. (Pubmed Central) -  Apr 3, 2024   
    Mifepristone-induced adipocytes are closer to the in situ adipocytes than those induced by the conventional protocol. The present study proposes a single treatment with mifepristone as a novel protocol to induce more physiologically relevant adipocytes in 3T3-L1 cells than the conventional protocol.
  • ||||||||||  Mifeprex (mifepristone) / Danco Laboratories
    Uterine Tissue-Resident Natural Killer Cells Derived from Conventional Natural Killer Cells are (Exhibit Hall F1; Poster Board Number: B726) -  Mar 29, 2024 - Abstract #IMMUNOLOGY2024IMMUNOLOGY_1592;    
    We found that mice OVX at three weeks of age and analyzed as adults did not have trNK cells in the uterine tissue unless progesterone (P4) was administered...Delivery of P4 to OVX or intact mice induced the expansion of cNK-derived trNK cells which was abrogated if RU486 was administered...Finally, sorted cNK cells transferred into OVX mice supplemented with P4 differentiated into trNK cells in the uterus, but not the spleen. Taken together, we identified a novel differentiation pathway for uterine trNK cells tightly regulated by P4 in the uterine tissue.
  • ||||||||||  Mifeprex (mifepristone) / Danco Laboratories
    Uterine Tissue-Resident Natural Killer Cells Derived from Conventional Natural Killer Cells are (Room W179) -  Mar 22, 2024 - Abstract #IMMUNOLOGY2024IMMUNOLOGY_234;    
    We found that mice OVX at three weeks of age and analyzed as adults did not have trNK cells in the uterine tissue unless progesterone (P4) was administered...Delivery of P4 to OVX or intact mice induced the expansion of cNK-derived trNK cells which was abrogated if RU486 was administered...Finally, sorted cNK cells transferred into OVX mice supplemented with P4 differentiated into trNK cells in the uterus, but not the spleen. Taken together, we identified a novel differentiation pathway for uterine trNK cells tightly regulated by P4 in the uterine tissue.
  • ||||||||||  Mifeprex (mifepristone) / Danco Laboratories
    Journal:  Outpatient medical management of later second trimester abortion (18-23.6 weeks) with procedural evacuation backup: A large case series. (Pubmed Central) -  Mar 22, 2024   
    We conducted a retrospective medical records review of adult patients who received mifepristone and repeated misoprostol for second trimester abortion with procedural evacuation backup at an Arizona clinic between October 2017 and November 2021...Outpatient settings may consider medical management of abortion between 18 and 24 weeks with procedural evacuation back-up as a safe, effective, and manageable second trimester abortion option. Additional research is needed on patient experience and satisfaction.
  • ||||||||||  Mifeprex (mifepristone) / Danco Laboratories
    Preclinical, Journal:  Mifepristone decreases nicotine intake in dependent and non-dependent adult rats. (Pubmed Central) -  Mar 18, 2024   
    Moreover, mifepristone decreased the distance traveled and rearing in the open field test and operant responding for food pellets. These findings indicate that mifepristone decreases nicotine intake but this effect may be partially attributed to the sedative effects of mifepristone.
  • ||||||||||  Mifeprex (mifepristone) / Danco Laboratories
    Trial completion:  Mail Order Mifepristone Study (clinicaltrials.gov) -  Mar 7, 2024   
    P4,  N=538, Completed, 
    No abstract available Active, not recruiting --> Completed
  • ||||||||||  Mifeprex (mifepristone) / Danco Laboratories
    Context dependent role of glucocorticoids in breast cancer. (Section 38) -  Mar 5, 2024 - Abstract #AACR2024AACR_7944;    
    et al, indicates that glucocorticoids have an oncogenic role and furthermore promote breast cancer metastasis in TNBC model thereby validating the subtype and context dependent role of the glucocorticoid receptor. We are currently exploring the mechanism of GR's context-dependent tumor suppressor and oncogenic role in distinct breast cancer subtypes.
  • ||||||||||  Apristor (onapristone XR) / Context Therap, Mifeprex (mifepristone) / Danco Laboratories
    Immune targeting progesterone receptor in hormone receptor positive breast cancer (Section 1) -  Mar 5, 2024 - Abstract #AACR2024AACR_7038;    
    We developed a PR vaccine that elicited PR-specific T cell responses in vivo. We are currently examining the mechanisms that underlie PR-mediated immunosuppression and exploring the potential of PR vaccines in HR?BC.
  • ||||||||||  progesterone / Generic mfg.
    Journal:  Progesterone increases hepatic lipid content and plasma lipid levels through PR- B-mediated lipogenesis. (Pubmed Central) -  Mar 4, 2024   
    The lipid balance between lipogenesis and lipolysis determines fat build-up and is linked to lipid metabolism dysfunction, which involves the breakdown and storage of fats for energy and the synthesis of structural and functional lipids. Therefore, P4 may impact the lipid metabolism and reproductive development during gestation.
  • ||||||||||  Mifeprex (mifepristone) / Danco Laboratories
    Journal:  One-day versus two-day mifepristone-misoprostol interval prior to initiation of misoprostol during late second trimester medication abortion: a cohort study. (Pubmed Central) -  Mar 4, 2024   
    Overnight mifepristone at the time of cervical dilator placement is a safe and effective alternative to adjuvant same-day misoprostol for cervical preparation prior to D&E and may offer benefits for clinic flow and patient experience. Compared to one-day interval, administration of mifepristone two days prior to misoprostol initiation has a shorter interval of induction to expulsion and a higher rate of abortion completion within 12 hours of initiation of misoprostol during late second trimester medication abortion.
  • ||||||||||  daporinad (APO866) / Valerio Therap, Mifeprex (mifepristone) / Danco Laboratories
    Journal:  Nicotine regulates abnormal macrophage polarization and trophoblast invasion associated with preterm labor via the ?7nAChR/SIRT1 axis. (Pubmed Central) -  Feb 26, 2024   
    Compared to one-day interval, administration of mifepristone two days prior to misoprostol initiation has a shorter interval of induction to expulsion and a higher rate of abortion completion within 12 hours of initiation of misoprostol during late second trimester medication abortion. Nicotine regulated abnormal macrophage polarization and trophoblast invasion associated with PTL via the ?7nAChR/SIRT1 axis.
  • ||||||||||  Mifeprex (mifepristone) / Danco Laboratories
    Journal:  Geographic Access to Early Pregnancy Loss Management. (Pubmed Central) -  Feb 19, 2024   
    Rural and higher deprivation areas had statistically significantly lower adjusted odds ratios for comprehensive management (0.03-0.07 and 0.3-0.4, respectively) and aspiration (0.03-0.06 and 0.1-0.3, respectively) access. Mifepristone and uterine aspiration implementation would address disparate access to EPL treatment.
  • ||||||||||  Mifeprex (mifepristone) / Danco Laboratories
    Journal:  Effectiveness and safety of telehealth medication abortion in the USA. (Pubmed Central) -  Feb 16, 2024   
    We assessed effectiveness, defined as complete abortion after 200?mg mifepristone and 1,600??g misoprostol (or lower) without additional intervention; safety was measured by the absence of serious adverse events...There were no differences in effectiveness or safety between synchronous and asynchronous models of care. Telehealth medication abortion is effective, safe and comparable to published rates of in-person medication abortion care.
  • ||||||||||  Enbrel (etanercept) / Pfizer, Amgen, Mifeprex (mifepristone) / Danco Laboratories
    Trial primary completion date:  TNF and Glucocorticoid Antagonist for GWI Associated Multi-symptom Disease Homeostasis Reset (clinicaltrials.gov) -  Feb 15, 2024   
    P1,  N=20, Recruiting, 
    Telehealth medication abortion is effective, safe and comparable to published rates of in-person medication abortion care. Trial primary completion date: Dec 2023 --> Jul 2024